This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| HMG-CoA reductase | |
|---|---|
| Name | HMG-CoA reductase |
| Organism | Homo sapiens |
| Ec | 1.1.1.34 |
HMG-CoA reductase is a membrane-associated enzyme central to sterol biosynthesis and cellular isoprenoid production. It catalyzes the NADPH-dependent conversion of 3-hydroxy-3-methylglutaryl-CoA to mevalonate, linking signals from Wall Street to National Institutes of Health-funded research through pharmaceutical development and public health policy debates. Work on the enzyme intersects with research institutions such as Harvard University, Massachusetts Institute of Technology, University of Cambridge, University of Oxford, and regulatory decisions by Food and Drug Administration, European Medicines Agency, and World Health Organization.
The enzyme is an integral membrane protein of the endoplasmic reticulum with a transmembrane N-terminal domain and a cytosolic catalytic C-terminal domain; structural studies from groups at Max Planck Society, Salk Institute, and Rockefeller University have used crystallography methods developed alongside techniques at Brookhaven National Laboratory and Argonne National Laboratory. Catalysis proceeds via a sequential bi-bi mechanism involving two molecules of NADPH; mechanistic insights were advanced by investigators affiliated with Cold Spring Harbor Laboratory, Johns Hopkins University, and Stanford University. High-resolution structures reveal a catalytic tetrad and substrate-binding pocket conserved across taxa studied at University of California, Berkeley, University of Tokyo, and Karolinska Institute, informing inhibitor design pursued by teams at Pfizer, Merck & Co., and Novartis. Electron density maps and cryo-EM reconstructions from facilities at EMBL and European Synchrotron Radiation Facility clarified conformational changes associated with catalysis, echoing theoretical frameworks from Imperial College London and computational models from Lawrence Berkeley National Laboratory.
Regulatory mechanisms include sterol-mediated feedback affecting transcription via sterol regulatory element-binding proteins studied at Yale University, post-translational phosphorylation by AMP-activated protein kinase characterized by researchers at University of Cambridge and University of Toronto, and ubiquitin-mediated degradation pathways elucidated in collaborations involving Cold Spring Harbor Laboratory and National Institutes of Health. Hormonal control links work in endocrinology from Mayo Clinic, Cleveland Clinic, and UCLA to metabolic regulation in studies funded by Wellcome Trust and Howard Hughes Medical Institute. Cellular trafficking and proteasomal turnover have been probed using model systems from Massachusetts General Hospital and University of Michigan, while population-level regulation has been debated in policy circles at Centers for Disease Control and Prevention and World Bank meetings.
The enzyme sits at a branch point yielding mevalonate, a precursor for cholesterol, ubiquinone, dolichol, and prenylated proteins; pathway mapping has been integrated into biochemical atlases produced by National Center for Biotechnology Information, European Bioinformatics Institute, and Protein Data Bank. Intersections with mitochondrial function have been explored by investigators at Columbia University, Princeton University, and University of Pennsylvania, linking to cardiovascular research centers including Cleveland Clinic, Johns Hopkins Hospital, and Mount Sinai Health System. The role in lipid homeostasis ties into clinical studies from Brigham and Women’s Hospital, population cohorts like Framingham Heart Study, and large consortia such as CARDIoGRAMplusC4D.
Therapeutic targeting spawned statin development by teams at Merck & Co., AstraZeneca, and Pfizer and regulatory approval processes at Food and Drug Administration and European Medicines Agency. Clinical trials led by groups at Duke University, Oxford University Clinical Trials Unit, and Mayo Clinic established efficacy in reducing cardiovascular events reported in journals associated with New England Journal of Medicine, The Lancet, and Journal of the American Medical Association. Adverse effect monitoring has engaged pharmacovigilance offices at World Health Organization and European Medicines Agency, while translational programs at National Institutes of Health and biotech firms such as Genentech explore next-generation inhibitors and combination therapies informed by oncologic research at MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center.
Variants in the HMGCR gene correlate with lipid phenotypes identified in genome-wide association studies conducted by consortia including GIANT Consortium, Global Lipids Genetics Consortium, and population biobanks like UK Biobank and dbGaP. Studies from Harvard School of Public Health, Stanford School of Medicine, and Karolinska Institutet link polymorphisms to statin response, informing pharmacogenomics initiatives at Clinical Pharmacogenetics Implementation Consortium and precision medicine programs at NIH All of Us Research Program. Mendelian disorders of cholesterol biosynthesis studied at Boston Children’s Hospital and Great Ormond Street Hospital provide context for rare pathogenic variants and developmental phenotypes reported in cohorts assembled by EuroGentest.
Biochemical assays measuring enzyme activity employ spectrophotometric NADPH consumption methods standardized in laboratories at Scripps Research Institute, Weizmann Institute of Science, and Riken. Structural biology uses X-ray crystallography and cryo-EM performed at Diamond Light Source, Argonne National Laboratory, and EMBL-EBI; mass spectrometry workflows from Thermo Fisher Scientific platforms and proteomics centers at European Proteomics Organisation quantify post-translational modifications. Cellular assays leveraging CRISPR gene editing developed at Broad Institute and Zuckerman Institute probe regulatory networks, while clinical biochemistry labs in systems at Mayo Clinic Laboratories and Quest Diagnostics support lipid panels used in trials coordinated by World Health Organization and National Heart, Lung, and Blood Institute.
Category:Enzymes